DC
ACHV icon

Diametric Capital’s Achieve Life Sciences ACHV Stock Holding History

Diametric Capital’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Buy
81,179
+62,528
+335% +$298K 0.06% 321
2026
Q1 		$54.8K Buy
+18,651
New +$82.8K 0.01% 451
2024
Q1 		– Sell
-18,753
Closed -$77.3K – 326
2023
Q4 		$77.3K Sell
18,753
-60,457
-76% -$263K 0.05% 231
2023
Q3 		$341K Sell
79,210
-4,868
-6% -$24.5K 0.14% 201
2023
Q2 		$436K Buy
84,078
+37,679
+81% +$264K 0.19% 144
2023
Q1 		$316K Buy
46,399
+26,496
+133% +$126K 0.15% 193
2022
Q4 		$48.8K Sell
19,903
-14,757
-43% -$37.9K 0.02% 266
2022
Q3 		$114K Buy
34,660
+15,153
+78% +$72.3K 0.06% 235
2022
Q2 		$95K Buy
+19,507
New +$132K 0.07% 225

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Diametric Capital's ACHV Position: Q2 2026 in Review

Diametric Capital increased its Achieve Life Sciences (ACHV) stake by 335% in Q2 2026, buying an estimated $298K and bringing the position to 81,179 shares worth $530K. The position accounts for 0.06% of the portfolio, ranked #321.

Diametric Capital first reported a position in ACHV in Q2 2022 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Diametric Capital held 81,179 shares of Achieve Life Sciences worth $530K as of Q2 2026.
  • Diametric Capital bought 62,528 Achieve Life Sciences shares in Q2 2026, an estimated $298K.
  • Achieve Life Sciences made up 0.06% of Diametric Capital's portfolio in Q2 2026, its #321 holding.
  • Diametric Capital first reported a position in Achieve Life Sciences in Q2 2022 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.